Metraipolis › archive › dc_293fba70484e

Atidarsagene autotemcel — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Atidarsagene_autotemcel
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-10T06:50:09.340Z
SHA-256 of the archived text
3f54ca2ba5e7bd5e92bceb52490f96dc43d6d30283ea7c8d56bbe43b0a645859
Stable URL of this page
https://metraipolis.com/documento/dc_293fba70484e

How to cite

Atidarsagene autotemcel — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Atidarsagene_autotemcel (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_293fba70484e (Metraipolis archive dc_293fba70484e, sha256 3f54ca2ba5e7bd5e92bceb52490f96dc43d6d30283ea7c8d56bbe43b0a645859)
BibTeX
@misc{dc293fba70484e,
  title = {Atidarsagene autotemcel — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Atidarsagene_autotemcel},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_293fba70484e; sha256 3f54ca2ba5e7bd5e92bceb52490f96dc43d6d30283ea7c8d56bbe43b0a645859},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Atidarsagene_autotemcel. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Atidarsagene autotemcel, sold under the brand name Libmeldy among others, is a gene therapy treatment for metachromatic leukodystrophy developed by Orchard Therapeutics. It contains an autologous CD34⁺ cell enriched population that contains haematopoietic stem and progenitor cells transduced using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. The most common side effects include fever and low white blood cell count, mouth sores, respiratory infections, rash, medical line infections, viral infections, fever, gastrointestinal infections and enlarged liver. Atidarsagene autotemcel was authorized for medical use in the European Union in December 2020, in the United Kingdom in February 2021, and in the United States in March 2024. It is the first gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of metachromatic leukodystrophy.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Atidarsagene autotemcel» — https://en.wikipedia.org/wiki/Atidarsagene_autotemcel
Wikidata Q108887202: «gene therapy» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q108887202
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Atidarsagene_autotemcel?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1367172816, consultata il 2026-11-10T06:47:07.044Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 00ecc5bdc05c8297c1ae6182e5465586659ef804bbf674963316ccdfafba2298